Navigation Links
Shares Of AVI BioPharma Drops On Reports Of Disappointing Early Drug Trail

Shares of AVI BioPharma Inc. has lost a third of their value on Wednesday after the company reported disappointing clinical trial data for its experimental treatment against the hepatitis C virus. //

The shares of AVI were down $2.43, or 33 percent, to $4.83, in the heavy morning trade on the Nasdaq.

The Portland, Oregon based biotechnology company said that the results came from the second stage of a trial involving the antisense drug, called AVI-4065, among patients infected with the liver-damaging virus. Company officials have said that the drug showed favourable safety in all patients treated so far, but patients have experienced only a mean "slight decrease" in the amount of virus in their bloodstreams both during and after treatment.

In a press release the company officials said that during the 14 days of treatment, three of five patients evaluated had an initial decrease in viral load, whereas two of five exhibited little initial change. They were quick to point out that the results were still only preliminary and in only a small number of patients, and that patients remained enrolled in the study. They stated that the formal results of the trial were expected around the end of the year.

Antisense drugs, like AVI-4065, are artificial pieces of genetic material that are meant to prevent genes from expressing disease-causing proteins. Sadly the technology has not yet achieved great success despite high earlier hopes.


'"/>




Page: 1

Related medicine news :

1. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
2. Sun Pharma Allots Shares Upon Fccbs Conversion
3. Zenotech Issues 20 Lakh Shares to Ranbaxy for Rs 20 Cr
4. Female Ratio Drops Alarmingly In Himachal Due To Feticides
5. 1.8 mn Delhi Children to Receive Anti-polio Drops
6. Antibiotic Ear Drops Favored Over Oral Antibiotics for Ear Infections
7. No Smoking During Play Rehearsals: UK’s Health Ministry Drops the Curtain
8. Russia Reports First SARS Case
9. Uganda Reports Failure To Contain Sleeping Sickness
10. Reports of Hantavirus infection in India raise concerns
11. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology: